Literature DB >> 31531846

Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.

Elizabeth M Kander1, Qiuhong Zhao1, Seema A Bhat1, Jessica Hirsch2, John C Byrd1,3, Lauren Ooka4, Tracy Wiczer5, Jennifer A Woyach1, Farrukh T Awan1, Kerry A Rogers1, Tzu-Fei Wang1.   

Abstract

Entities:  

Keywords:  chronic lymphocytic leukaemia; ibrutinib; non-Hodgkin lymphoma; thrombosis (arterial); thrombosis (venous)

Mesh：

Substances：

Year:  2019        PMID： 31531846      PMCID： PMC6819220          DOI： 10.1111/bjh.16209

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.

Authors:  Darryl P Leong; François Caron; Christopher Hillis; Annie Duan; Jeff S Healey; Graeme Fraser; Deborah Siegal
Journal:  Blood       Date:  2016-05-31       Impact factor: 22.113

2.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

3.  Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Andrew H Lipsky; Mohammed Z H Farooqui; Xin Tian; Sabrina Martyr; Ann M Cullinane; Khanh Nghiem; Clare Sun; Janet Valdez; Carsten U Niemann; Sarah E M Herman; Nakhle Saba; Susan Soto; Gerald Marti; Gulbu Uzel; Steve M Holland; Jay N Lozier; Adrian Wiestner
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

4.  Venous thromboembolism in patients with chronic lymphocytic leukemia.

Authors:  M Šimkovič; P Vodárek; M Motyčková; D Belada; F Vrbacký; P Žák; L Smolej
Journal:  Thromb Res       Date:  2015-05-20       Impact factor: 3.944

5.  Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Authors:  Tracy E Wiczer; Lauren B Levine; Jessica Brumbaugh; Jessica Coggins; Qiuhong Zhao; Amy S Ruppert; Kerry Rogers; Anli McCoy; Luay Mousa; Avirup Guha; Nyla A Heerema; Kami Maddocks; Beth Christian; Leslie A Andritsos; Samantha Jaglowski; Steven Devine; Robert Baiocchi; Jennifer Woyach; Jeffrey Jones; Michael Grever; Kristie A Blum; John C Byrd; Farrukh T Awan
Journal:  Blood Adv       Date:  2017-09-08

Review 6.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

7.  Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism.

Authors:  Annika M Whittle; David J Allsup; James R Bailey
Journal:  Leuk Res       Date:  2010-12-14       Impact factor: 3.156

8.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Authors:  Ariela Noy; Sven de Vos; Catherine Thieblemont; Peter Martin; Christopher R Flowers; Franck Morschhauser; Graham P Collins; Shuo Ma; Morton Coleman; Shachar Peles; Stephen Smith; Jacqueline C Barrientos; Alina Smith; Brian Munneke; Isaiah Dimery; Darrin M Beaupre; Robert Chen
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 10.  Targets for Ibrutinib Beyond B Cell Malignancies.

Authors:  A Berglöf; A Hamasy; S Meinke; M Palma; A Krstic; R Månsson; E Kimby; A Österborg; C I E Smith
Journal:  Scand J Immunol       Date:  2015-09       Impact factor: 3.487
  10 in total
  3 in total

1.  Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.

Authors:  Nichola Cooper; Ivy Altomare; Mark R Thomas; Phillip L R Nicolson; Steve P Watson; Vadim Markovtsov; Leslie K Todd; Esteban Masuda; James B Bussel
Journal:  Ther Adv Hematol       Date:  2021-04-30

2.  Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.

Authors:  Christophe Bonnet; Jehan Dupuis; Hervé Tilly; Thierry Lamy; Christophe Fruchart; Steven le Gouill; Catherine Thieblemont; Franck Morschhauser; Olivier Casasnovas; Krimo Bouabdallah; Hervé Ghesquieres; Eric Van Den Neste; Marc André; Guillaume Cartron; Gilles Salles
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.575

3.  Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.

Authors:  Zemene Demelash Kifle
Journal:  Metabol Open       Date:  2021-07-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.